<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4740">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742702</url>
  </required_header>
  <id_info>
    <org_study_id>R06086M</org_study_id>
    <secondary_id>2006-002065-39</secondary_id>
    <secondary_id>2009-014542-29</secondary_id>
    <secondary_id>R07110M</secondary_id>
    <secondary_id>R07053M</secondary_id>
    <secondary_id>R08012</secondary_id>
    <secondary_id>R09103M</secondary_id>
    <secondary_id>R10056</secondary_id>
    <secondary_id>R06086M</secondary_id>
    <nct_id>NCT01742702</nct_id>
  </id_info>
  <brief_title>Haemodynamics in Hypertension</brief_title>
  <acronym>DYNAMIC</acronym>
  <official_title>HaemoDYNAMICs in Primary and Secondary Hypertension: the DYNAMIC-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnish Foundation for Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paavo Nurmi Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sigrid Juselius Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Cultural Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere Tuberculosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Competitive Research Funding of Pirkanmaa Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarne Koskelo Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orion Farmos Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tampere</source>
  <oversight_info>
    <authority>Finland: Finnish National Agency for Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to examine the haemodynamic changes in primary and
      secondary hypertension with a non-invasive haemodynamic measurement protocol utilizing
      radial pulse wave analysis and whole-body impedance cardiography in both supine position and
      during head-up tilt.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated blood pressure (BP) and related cardiovascular complications are the leading causes
      of morbidity and mortality in the modern world. In routine clinical practice, the
      haemodynamic status is commonly assessed by measuring heart rate and blood pressure at rest,
      which provides only limited information about functional haemodynamic status. In addition,
      the haemodynamic changes resulting in similar elevations of BP may differ substantially
      between patients and disorders.

      Therefore, we investigated the haemodynamic changes in primary and secondary hypertension
      and in the control subjects with non-invasive radial pulse wave analysis and whole-body
      impedance cardiography. The method includes the determination of peripheral and central BP,
      cardiac function, vascular resistance, arterial compliance and indices of pulse wave
      reflection. Besides the measurements performed in the supine position, passive orthostatic
      challenge is included to the protocol to assess functional haemodynamic status. In addition,
      the effects of single doses of two largely endothelium-dependent agents, inhaled salbutamol
      and intravenous L-arginine, and one endothelium-independent agent, sublingual nitroglycerin,
      were investigated. The repeatability and reproducibility of the protocol was first examined
      with a double-blind, randomized protocol in 35 subjects (methodological study group), and
      after that the administration of research drugs has been open-label. The study population
      consists of 7 subgroups, as described below. The study protocol of each subgroup has been
      approved by the ethics committee of the Pirkanmaa Hospital District (Ethics committee ID's
      above), and the administration of research drugs has also been approved by the Finnish
      Agency for Medicines (EudraCT-numbers above).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in haemodynamic variables during the follow-up</measure>
    <time_frame>baseline, one year, ten years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Haemodynamic measurements are performed at baseline, after one year and after 10 years of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic response to head-up tilt and research drugs</measure>
    <time_frame>0, 5, 10, 15, 20, 25 and 30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rapid haemodynamic responses are assessed during the same measurement session (the response to head-up tilt and to research drugs salbutamol, nitroglycerin and L-arginine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic response to bisoprolol or dietary supplements (liquorice, milk casein-derived polypeptides)</measure>
    <time_frame>baseline and after 2 weeks (liquorice); 3 weeks (bisoprolol), or 12 weeks (polypeptides)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in haemodynamic variables after daily consumption of liquorice (2 weeks); bisoprolol (3 weeks); small milk casein-derived polypeptides (12 weeks)</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Primary Hypertension</condition>
  <condition>Secondary Hypertension</condition>
  <condition>Aortic Stenosis</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>DYNAMIC</arm_group_label>
    <description>Subjects with primary or secondary hypertension and normotensive control subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AERO-DYNAMIC</arm_group_label>
    <description>Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquorice</arm_group_label>
    <description>Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk polypeptides</arm_group_label>
    <description>Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol</arm_group_label>
    <description>Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic stenosis</arm_group_label>
    <description>Subjects with aortic stenosis confirmed by echocardiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methodological</arm_group_label>
    <description>35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin 0.25 mg (single dose)</intervention_name>
    <description>Single dose of sublingual nitroglycerin to examine acute haemodynamic effects</description>
    <arm_group_label>DYNAMIC</arm_group_label>
    <arm_group_label>AERO-DYNAMIC</arm_group_label>
    <arm_group_label>Liquorice</arm_group_label>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_label>Aortic stenosis</arm_group_label>
    <arm_group_label>Methodological</arm_group_label>
    <other_name>Nitro resoriblet, Orion Pharma, Espoo, Finland</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol 400 µg (single dose)</intervention_name>
    <description>Single dose of inhaled salbutamol to examine acute haemodynamic effects</description>
    <arm_group_label>DYNAMIC</arm_group_label>
    <arm_group_label>AERO-DYNAMIC</arm_group_label>
    <arm_group_label>Liquorice</arm_group_label>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_label>Aortic stenosis</arm_group_label>
    <arm_group_label>Methodological</arm_group_label>
    <other_name>Ventoline, GlaxoSmithKline, Uxbridge, Middlesex, UK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine (10 min infusion)</intervention_name>
    <description>L-arginine infusion 10 mg/kg/min for 10 minutes to examine acute haemodynamic effects</description>
    <arm_group_label>Methodological</arm_group_label>
    <other_name>L-arginine hydrochloride 20 mg ml/l, B. Braun Melsungen Ag, Melsungen, Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Liquorice (2 weeks, glycyrrhizin 290-370 mg daily)</intervention_name>
    <description>Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention</description>
    <arm_group_label>Liquorice</arm_group_label>
    <other_name>Halva liquorice (TM), Kouvola liquorice (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Small milk casein-derived polypeptides (yoghurt, 12 weeks daily)</intervention_name>
    <description>Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention</description>
    <arm_group_label>Milk polypeptides</arm_group_label>
    <other_name>Valio (TM) evolus yoghurt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol (5mg daily for 3 weeks)</intervention_name>
    <description>Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions.</description>
    <arm_group_label>Bisoprolol</arm_group_label>
    <other_name>Emconcor 5 mg, Merck KGaA, Darmstadt, Germany</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult hypertensive and normotensive subjects who were treated in Tampere University
        Hospital clinics of internal medicine or cardiology, or visited medical doctors as
        outpatients in several occupational health care providers in the Pirkanmaa Hospital
        District.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Independent, community-dwelling adults

          -  Hypertensive subjects (primary or secondary hypertension)

          -  Normotensive control subjects

          -  Subjects with aortic stenosis (subgroup &quot;aortic stenosis&quot;)

        Exclusion Criteria:

          -  Pregnancy

          -  Systolic blood pressure &lt;90 mmHg

          -  Allergies to test compounds
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilkka Pörsti, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tampere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Tampere</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilkka Pörsti, MD, PhD, Professor</last_name>
      <email>ilkka.porsti@uta.fi</email>
    </contact>
    <investigator>
      <last_name>Ilkka Pörsti, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilkka Pörsti, Professor</last_name>
      <email>ilkka.porsti@uta.fi</email>
    </contact>
    <investigator>
      <last_name>Ilkka Pörsti, MD, PhD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 3, 2012</lastchanged_date>
  <firstreceived_date>November 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tampere</investigator_affiliation>
    <investigator_full_name>Ilkka Porsti</investigator_full_name>
    <investigator_title>MD, PhD, Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Arterial stiffness</keyword>
  <keyword>Cardiac output</keyword>
  <keyword>Vascular resistance</keyword>
  <keyword>Pulse wave reflection</keyword>
  <keyword>Head-up tilt</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Caseins</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Glycyrrhizic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
